Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

Beth Israel Deaconess Medical Center and Navigenics, Inc., a leading personal genomics company, today announced a collaboration to make personalized genomics available to doctors in training.

21 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Pine Hills Kiddie Garden of Fort Wayne, Ind., will take necessary steps to ensure that a child's diabetes care is integrated into the usual routine of its day care center and programs as part of a settlement to resolve allegations that it discriminated on the basis of disability, the Justice Department announced today.

20 Oct 2009

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

Children with history of diabetic ketoacidosis may have memory problems

Children who have had an episode of diabetic ketoacidosis, a common complication of diabetes, may have persistent memory problems, according to a new study from researchers at the UC Davis Center for Mind and Brain.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

Innovative tool for providing patient-centered care for diabetics

Mayo Clinic clinicians and designers, along with colleagues from other institutions, have developed and tested a tool to involve patients more in their diabetes treatment and medication choices.

19 Oct 2009

NFL, NDC launch 'Fuel Up to Play 60' to tackle childhood obesity

The NFL and National Dairy Council (NDC) today launch Fuel Up to Play 60, a new initiative aimed at tackling childhood obesity by giving youth a voice in changing the school nutrition and physical activity environment. The program will reach 36 million youth in 60,000 elementary, middle and high schools during the 2009/2010 school year.

15 Oct 2009

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009

"A Stroke of Health" for the weight loss benefits of healthy eating

Friday the 13th in June 2008 started out as a normal day for Bob and Judi Swartz, but the day would end as anything but ordinary. Bob would suffer a serious stroke and Judi would take the first steps in a year-long journey of recovery and discovery.

15 Oct 2009

National Institutes of Health grants $12 million to WCDRC for obesity research

The Miriam Hospital's Weight Control and Diabetes Research Center (WCDRC) recently received six research grants from the National Institutes of Health - totaling more than $12 million in funding - that will support the work of researchers focused on the prevention and treatment of obesity.

15 Oct 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

New findings from ADVANCE clinical trial presented

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

New diabetes algorithm released by AACE for the management of type 2 diabetes

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

New results from ADVANCE provide important insights to reduce diabetes complications

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Diabetes represents a global health threat

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Children with history of diabetic ketoacidosis may have memory problems

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Innovative tool for providing patient-centered care for diabetics

NFL, NDC launch 'Fuel Up to Play 60' to tackle childhood obesity

Resveratrol in red grapes offers some protection against diabetes

"A Stroke of Health" for the weight loss benefits of healthy eating

National Institutes of Health grants $12 million to WCDRC for obesity research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in